Evidence map›Paper›PMID 37884284›Full record

ArticleThe Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology2023

Three sesquiterpene lactones suppress lung adenocarcinoma by blocking TMEM16A-mediated Ca

Ruilian Xiu, Jie Jia, Qing Zhang, Fengjiao Liu, Yaxin Jia, Yuanyuan Zhang, Beibei Song, Xiaodan Liu, Jingwei Chen, Dongyang Huang and 5 more

Open access · diamondAbstract read
In one paragraph

Article in The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Pathogens (Basel, Switzerland) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Ruilian XiuDepartment of Pharmacology, Hebei University of Chinese Medicine, Shijiazhuang 050200, China.
Jie JiaDepartment of Pharmacology, Hebei University of Chinese Medicine, Shijiazhuang 050200, China.
Qing ZhangCollege of Basic Medicine, Hebei University of Chinese Medicine, Shijiazhuang 050200, China.
Fengjiao LiuDepartment of Pharmacology, Hebei University of Chinese Medicine, Shijiazhuang 050200, China.
Yaxin JiaDepartment of Pharmacology, Hebei University of Chinese Medicine, Shijiazhuang 050200, China.
Yuanyuan ZhangDepartment of Pharmacology, Hebei University of Chinese Medicine, Shijiazhuang 050200, China.
Beibei SongThe First Department of Pulmonary and Critical Care Medicine, The Second Hospital of Hebei Medical University, Shijiazhuang 050000, China.
Xiaodan LiuThe First Department of Pulmonary and Critical Care Medicine, The Second Hospital of Hebei Medical University, Shijiazhuang 050000, China.
Jingwei ChenHebei Key Laboratory of Integrative Medicine on Liver-Kidney Patterns, Hebei University of Chinese Medicine, Shijiazhuang 050200, China.
Dongyang HuangInstitute of Chinese Integrative Medicine, Hebei Medical University, Shijiazhuang 050017, China.
Fan ZhangHebei Higher Education Applied Technology Research Center of TCM Development and Industrialization, Hebei University of Chinese Medicine, Shijiazhuang 050200, China.
Juanjuan MaHebei International Cooperation Center for Ion Channel Function and Innovative Traditional Chinese Medicine, Shijiazhuang 050091, China.
Honglin LiDepartment of Pharmacy, Hebei Provincial Hospital of Traditional Chinese Medicine, Shijiazhuang 050000, China.
Xuan ZhangDepartment of Pharmacology, Hebei University of Chinese Medicine, Shijiazhuang 050200, China.
Yunyun GengDepartment of Pharmacology, Hebei University of Chinese Medicine, Shijiazhuang 050200, China.
Hebei University of Chinese Medicine · CNHebei Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Transmembrane protein TMEM16A, which encodes calcium-activated chloride channel has been implicated in tumorigenesis. Overexpression of TMEM16A is associated with poor prognosis and low overall survival in multiple cancers including lung adenocarcinoma, making it a promising biomarker and therapeutic target. In this study, three structure-related sesquiterpene lactones (mecheliolide, costunolide and dehydrocostus lactone) were extracted from the traditional Chinese medicine

Indexed as

Adenocarcinoma of lungCostunolideDehydrocostus lactoneMecheliolideTMEM16A

Identifiers

PMID37884284
PMCPMC10613571
OpenAlexW4387966793

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.